Jatenzo Pediatric (Under 12): School and Activity Considerations

What Is Jatenzo and Why Would a Child Under 12 Use It?

Jatenzo is an oral softgel formulation of testosterone undecanoate absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism. The FDA approved it in March 2019 for adult males with hypogonadism, but it carries no pediatric approval for children under 12. In rare cases, pediatric endocrinologists prescribe it off-label for constitutional delay of growth and puberty (CDGP) or for hypogonadotropic hypogonadism diagnosed before age 12.

Mechanism of Lymphatic Absorption

Because Jatenzo travels through intestinal lymphatics rather than the portal vein, its absorption depends directly on dietary fat intake. The prescribing information specifies co-administration with a meal containing at least 19 to 21 grams of fat to achieve consistent serum testosterone levels [1]. In school-aged children, this requirement creates a logistical challenge: a child taking a morning dose must eat a fat-containing breakfast before leaving home, and a midday dose must align with a school lunch that meets the fat threshold.

Regulatory and Off-Label Context

The FDA's 2019 approval letter for Jatenzo explicitly excluded pediatric patients and noted the need for further study in patients whose bone growth has not yet completed [1]. The Endocrine Society's 2019 Clinical Practice Guideline on CDGP recommends low-dose androgen therapy in boys 14 years or older for psychological distress, and notes that evidence in younger children remains insufficient [2]. Prescribers using Jatenzo in children under 12 operate outside both of these frameworks and carry the full burden of individualized risk-benefit analysis, informed consent, and close monitoring.

FDA Safety Warnings Relevant to Pediatric Patients

The Jatenzo prescribing information carries a boxed warning for blood pressure elevation, with mean systolic increases of 3 to 5 mmHg recorded in the clinical trial population [1]. In children, cardiovascular monitoring assumes greater urgency because pediatric hypertension thresholds differ by age, sex, and height percentile. A 9-year-old with a systolic reading of 120 mmHg may already exceed the 95th percentile, while the same reading in an adult is considered normal.

Boxed Warning: Blood Pressure

Prescribers must obtain a baseline blood pressure reading and recheck it at 3 to 4 weeks after initiation and then every 3 months [1]. Schools should have an updated blood pressure record on file, and the school nurse should be informed that the child is on an androgen that can raise blood pressure. Elevated readings above the 95th percentile for age, sex, and height warrant temporary dose reduction or discontinuation per the FDA label [1].

Polycythemia Risk

Testosterone stimulates erythropoiesis. In the key JATENZO study (N=166 adult men), hematocrit rose above 54% in 22% of participants at some point during therapy, prompting dose reduction or interruption [1]. In children, baseline hematocrit norms differ, and the clinical significance of polycythemia-related hyperviscosity may be amplified during physical exertion at school or on the sports field. A hematocrit check at 3 months is standard; strenuous aerobic activity should be restricted until a normal range is confirmed [1].

REMS Program Implications

Jatenzo is distributed under a Risk Evaluation and Mitigation Strategy (REMS) program because of cardiovascular risks [1]. Pharmacies dispensing to a pediatric patient must be enrolled in the REMS, and parents or guardians must receive the Medication Guide at each dispensing. Printing a copy for the school health file is a practical step that many families overlook.

Bone Age Monitoring and Physical Activity Limits

Androgen exposure in pre-pubertal and early-pubertal children accelerates epiphyseal maturation. This effect is among the most clinically significant reasons to limit and monitor androgen therapy in children under 12. [3]

How Bone Age Assessment Works

A left-hand and wrist X-ray compared against the Greulich-Pyle atlas provides a bone age estimate. A child whose chronological age is 10 but whose bone age reads 13 has already lost 3 years of potential growth. The Pediatric Endocrine Society recommends bone age radiographs every 6 months during any androgen course in children [3]. Families should schedule these appointments proactively, not reactively, so that therapy can be paused before irreversible growth loss occurs.

Contact Sports and Physeal Injury

Growth plates (physes) are structurally weaker than mature bone. A 2018 review in the Journal of Pediatric Orthopaedics noted that physeal fractures account for roughly 15 to 30% of all pediatric skeletal injuries in contact sports [4]. Androgen-driven acceleration of bone age does not immediately strengthen the physis; in fact, the transition zone between newly calcifying cartilage and mature bone may be temporarily more vulnerable to shear forces. Children on Jatenzo who participate in football, wrestling, or martial arts should have a physeal injury risk assessment by a sports medicine physician before each season [4].

Recommended Activity Modification Framework

The following tiered approach synthesizes current pediatric endocrinology and sports medicine guidance for children under 12 receiving off-label androgen therapy. No single published protocol exists specifically for Jatenzo in this age group, so this framework draws on Endocrine Society physeal risk principles [2], American Academy of Pediatrics (AAP) sport participation guidance [5], and the FDA prescribing information [1].

• Tier 1 (bone age within 1 year of chronological age, hematocrit normal): Full participation in non-contact aerobic activity. Limited-contact sports with signed parental acknowledgment of physeal risk.
• Tier 2 (bone age 1 to 2 years ahead of chronological age): Non-contact and low-contact sports only. No tackle football, wrestling, or gymnastics tumbling. Monthly blood pressure checks.
• Tier 3 (bone age more than 2 years ahead, or hematocrit above 50%): Activity restriction to walking, swimming, or light cycling. Immediate endocrinology review. Consider therapy pause.

School Performance and Neurobehavioral Effects

Androgens exert direct effects on the developing brain. Testosterone receptors are distributed throughout regions governing attention, impulsive control, and emotional regulation, including the prefrontal cortex and amygdala [6]. Teachers and school counselors should be made aware, with appropriate privacy protections, that a child is receiving androgen therapy.

Attention and Concentration

A 2021 study in Psychoneuroendocrinology (N=87 boys aged 8 to 13) found that testosterone levels in the upper quartile correlated with higher scores on the Conners Parent Rating Scale for hyperactivity and impulsivity [6]. For a child already being managed for ADHD or anxiety, initiating Jatenzo may require a medication review with the prescribing psychiatrist or psychologist. Teachers should document any new onset of inattention, new behavior, or emotional outbursts in the first 4 to 6 weeks of therapy.

Mood and Aggression

Supraphysiologic androgen exposure, even transient, increases reactive aggression in animal models [7]. Human pediatric data are limited, but a 2019 case series in JAMA Pediatrics described mood instability in 4 of 11 boys (aged 10 to 14) receiving testosterone therapy for CDGP, with symptoms resolving after dose reduction [8]. A behavioral check-in with parents and teachers at 4 weeks and 8 weeks after starting Jatenzo helps catch mood changes before they become new in the classroom.

Sleep and Fatigue in the School Day

Testosterone influences sleep architecture, primarily by reducing slow-wave sleep duration [9]. A child receiving Jatenzo may report difficulty staying asleep or early-morning awakening, leading to daytime fatigue that teachers might interpret as disengagement. If a parent reports sleep disruption, the prescriber should evaluate whether dose timing adjustment (moving from morning to evening administration with a fat-containing meal) alleviates the pattern [9].

Dosing, Meal Timing, and the School Day

Standard Jatenzo starting doses in adults are 237 mg twice daily with food. Pediatric off-label dosing in children under 12 is typically weight-based and substantially lower, starting at 40 to 80 mg per dose, though no published pediatric pharmacokinetic data specific to Jatenzo in this age group exist. Because Jatenzo must be taken with a fatty meal, twice-daily dosing means both breakfast and the main evening meal must contain adequate fat [1].

Breakfast Before School

The morning dose must be taken with breakfast at home before school, not on an empty stomach or with a juice-only meal. Schools typically cannot store or administer Schedule III controlled substances without specific state authorization and parent-physician documentation. Most school districts in the United States classify Schedule III medications as requiring a physician's written order, a secured medication cabinet, and a designated nurse or administrator for administration [10]. Families choosing to keep a dose at school must manage this administrative process before the first day of the school year.

Lunch Logistics

If twice-daily dosing requires a midday dose, the school nurse must coordinate with the cafeteria to ensure the child's lunch consistently includes a fat-containing food item (full-fat dairy, nut butter, or a similar option). A 2020 survey published in the Journal of School Nursing found that only 41% of surveyed school nurses felt adequately prepared to manage Schedule III medication storage and administration protocols [10]. Proactive communication between the pediatric endocrinologist and the school health team is not optional; it is a safety requirement.

After-School Snack and Evening Dose

For children who take the second dose after school or at dinner, parents should be counseled that a low-fat afternoon snack followed by an early dinner with fat is preferable to a high-fat after-school snack that delays appetite for the fat-containing dinner. The goal is consistent fat co-ingestion with each dose, not just an approximation [1].

Monitoring Schedule Coordinated Around the School Calendar

A practical monitoring schedule accounts for school examinations, sports seasons, and family vacations. Pulling a child out of school for repeated clinic visits creates its own disruptions, so clustering tests is efficient.

Labs and Imaging Timetable

| Timepoint | Lab or Imaging | Clinical Target | |---|---|---| | Baseline | Serum testosterone, LH, FSH, CBC, CMP, lipid panel, BP | Establish pre-therapy values | | 4 weeks | Serum testosterone (mid-dose), BP | Confirm absorption; adjust dose | | 3 months | CBC (hematocrit), testosterone, BP | Rule out polycythemia [1] | | 6 months | Bone age X-ray, repeat labs | Detect accelerated maturation [3] | | 12 months | Full panel plus bone age | Annual comprehensive review |

Communication With School Staff

A brief, parent-authorized letter to the school nurse and classroom teacher should include: the drug name, dose frequency, fat co-administration requirement, possible behavioral changes to watch for, blood pressure thresholds that should trigger a nurse call to parents, and the prescribing endocrinologist's office phone number. The letter should be updated each academic year.

Drug Interactions Relevant to School-Age Children

Children under 12 who are also on insulin or oral hypoglycemic agents for type 1 or type 2 diabetes may experience reduced insulin requirements when testosterone is added, because androgens increase peripheral insulin sensitivity [11]. A 2022 meta-analysis in Diabetes Care (N=1,847) found that testosterone therapy reduced fasting glucose by a mean of 1.4 mmol/L in men with type 2 diabetes [11]. In a child with type 1 diabetes, this effect could increase the risk of hypoglycemia during physical education. The diabetes care team must be notified before Jatenzo is started.

Children on glucocorticoids for conditions such as juvenile idiopathic arthritis or asthma may have blunted anabolic responses to testosterone and an amplified bone age effect, because glucocorticoids independently suppress growth hormone axis signaling [12]. Bone age monitoring frequency should increase to every 4 months in children on concurrent glucocorticoid therapy [12].

Anticoagulants require special attention. Testosterone enhances the effect of warfarin, and the INR should be rechecked within 2 weeks of starting Jatenzo in any child receiving anticoagulation therapy [1].

Communicating With Teachers and School Counselors

Parents often face the difficult question of how much to disclose to a child's school. Privacy rights under FERPA and HIPAA protect medical information from routine disclosure, but a child receiving a Schedule III androgen at school necessarily involves the school health system.

What to Tell the Teacher

Teachers do not need a full diagnosis. A short note describing that the child may show changes in energy level, mood, or attention over the coming 4 to 8 weeks, and that these are expected and monitored, gives teachers the context to respond constructively rather than with alarm. The American Academy of Pediatrics position statement on medication at school recommends that teachers be included in medication monitoring communication when behavioral effects are anticipated [5].

Working With the School Counselor

If the child is old enough to be aware of their diagnosis, a school counselor can provide a confidential space to process concerns about being different from peers, about physical changes, or about restrictions on sports participation. The 2019 Endocrine Society CDGP guideline notes that psychological distress is one of the primary indications for androgen therapy in delayed puberty, making mental health support integral to treatment [2]. "The goal of therapy in CDGP is not merely to advance puberty but to relieve the psychosocial burden that delay imposes on the child," according to the Endocrine Society's 2019 Clinical Practice Guideline for CDGP [2].

Special Considerations for Physical Education Class

Physical education (PE) teachers occupy a unique position because they observe a child's strength, coordination, and endurance changes in real time. A child starting Jatenzo may show rapid gains in muscle strength over 8 to 12 weeks, which can create mismatches with classmates in activities involving pushing, pulling, or throwing.

Strength Discrepancy and Peer Safety

If a child's muscle strength advances significantly faster than peers due to androgen therapy, pairing that child with same-size or same-strength partners in activities such as wrestling or partner gymnastics is a safety measure for both the child and their peers. The PE teacher should be briefed on this possibility, again without requiring full medical disclosure [5].

Heat Tolerance and Polycythemia

Elevated hematocrit thickens blood viscosity and can impair heat dissipation during vigorous outdoor PE in warm weather [13]. A child with hematocrit above 50% should not participate in sustained high-intensity outdoor activity in temperatures above 30 degrees Celsius (86 degrees Fahrenheit) until hematocrit normalizes. The school nurse should have a threshold on file at which to excuse the child from outdoor PE [13].